Alpha 2 integrin +807 polymorphism in drug-induced gingival overgrowth.

Drug-induced gingival overgrowth remains a poorly understood side effect of certain medications. It is marked by abnormal collagen accumulation in the gums. Prior research has shown that fibroblasts contribute to this process through altered extracellular matrix regulation. However, the genetic basis for individual susceptibility is unclear. No prior work had resolved the role of integrin gene variants in this condition. The alpha2 integrin gene has been linked to collagen synthesis in other contexts. This gap motivated the current investigation into the +807 T/C polymorphism. The study aimed to clarify if this genetic variant influences the risk of drug-induced gingival overgrowth.

The study aimed to determine if the +807 T/C polymorphism in the alpha2 integrin gene affects the likelihood of drug-induced gingival overgrowth. This condition is known to occur in patients using calcium channel blockers. The researchers focused on a specific genetic variant due to its reported influence on integrin expression. They hypothesized that this polymorphism might correlate with the severity of the condition. The study compared individuals with and without the overgrowth. The goal was to identify whether the C allele at position +807 increases risk. This could help explain why some patients experience this side effect. The findings might guide future personalized treatment strategies.

The researchers conducted a case-control study involving 136 individuals using calcium channel blockers. Participants were divided into two groups based on the presence or absence of gingival overgrowth. Genetic analysis focused on the +807 T/C polymorphism in the alpha2 integrin gene. DNA was extracted from saliva or blood samples for genotyping. Statistical tools were used to compare allele frequencies between the groups. Odds ratios and confidence intervals were calculated to assess significance. The study controlled for potential confounding variables. The results were analyzed to determine the strength of the association.

The frequency of the +807 C allele was significantly higher in the case group than in the control group. The odds ratio was 3.61, with a 95% confidence interval of 2.14 to 6.10. This association was statistically significant at P < 0.05. No other polymorphisms were tested in this study. The C allele appears to increase the risk of drug-induced gingival overgrowth. The T allele was less common in individuals with the condition. These findings support the hypothesis that the +807 polymorphism influences susceptibility. The results suggest a clear genetic link to this side effect.

The study supports the hypothesis that the +807 C allele is a risk factor for drug-induced gingival overgrowth. The authors propose that this polymorphism influences alpha2 integrin expression. They suggest that this genetic variant may contribute to collagen accumulation in the gums. The findings do not claim causation but highlight a strong association. The study does not address how this variant interacts with environmental factors. The researchers do not propose new treatment strategies. They emphasize the need for further studies on this genetic marker. The results may guide future research into personalized medication plans.